Health Care • Biotechnology: Pharmaceutical Preparations
$1.75 ▲ +0.03
(+1.74%)
MKT CAP: $12.3M • VOL: 13.2K
52W L $2 52W H $7
ROARABLE / RQD
D- • 35/100
PIOTROSKI
3 / 9
HIND // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $319.7K | $8.0M | $8.7M |
| YoY Revenue Growth % | -96.0% | -7.7% | — |
| Gross Profit | $218.8K | $195.0K | — |
| Gross Margin % | 68.4% | 2.4% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$10.5M | -$1.0M | -$15.4M |
| Operating Margin % | -80.0% | -12.6% | -80.0% |
| Net Income (GAAP) | -$10.3M | -$1.4M | -$11.4M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$3.7M | -$614.1K | -$17.0M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$3.7M | -$614.1K | -$17.0M |
| FCF Margin % | -80.0% | -7.7% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $5.0M | $101.9K | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $3.8M | -$4.4M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR HIND.